An Endocellulase‐Triggered NO Targeted‐Release Enzyme‐Prodrug Therapy System and Its Application in Ischemia Injury
- 8 July 2024
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (29) , e2401599
Abstract
Nitric oxide (NO) is a crucial gaseous signaling molecules in regulating cardiovascular, immune, and nervous systems. Controlled and targeted NO delivery is imperative for treating cancer, inflammation, and cardiovascular diseases. Despite various enzyme‐prodrug therapy (EPT) systems facilitating controlled NO release, their clinical utility is hindered by nonspecific NO release and undesired metabolic consequence. In this study, a novel EPT system is presented utilizing a cellobioside‐diazeniumdiolate (Cel2‐NO) prodrug, activated by an endocellulase (Cel5A‐h38) derived from the rumen uncultured bacterium of Hu sheep. This system demonstrates nearly complete orthogonality, wherein Cel2‐NO prodrug maintains excellent stability under endogenous enzymes. Importantly, Cel5A‐h38 efficiently processes the prodrug without recognizing endogenous glycosides. The targeted drug release capability of the system is vividly illustrated through an in vivo near‐infrared imaging assay. The precise NO release by this EPT system exhibits significant therapeutic potential in a mouse hindlimb ischemia model, showcasing reductions in ischemic damage, ambulatory impairment, and modulation of inflammatory responses. Concurrently, the system enhances tissue repair and promotes function recovery efficacy. The novel EPT system holds broad applicability for the controlled and targeted delivery of essential drug molecules, providing a potent tool for treating cardiovascular diseases, tumors, and inflammation‐related disorders.Keywords
Funding Information
- Shanghai Jiao Tong University
- National Key Research and Development Program of China (2018YFE0200501)
- National Natural Science Foundation of China (32030063, 21877063, 81925021, 82102223)
This publication has 46 references indexed in Scilit:
- A novel bifunctional glucanase exhibiting high production of glucose and cellobiose from rumen bacteriumInternational Journal of Biological Macromolecules, 2021
- Polymeric Nitric Oxide Delivery Nanoplatforms for Treating Cancer, Cardiovascular Diseases, and InfectionAdvanced Healthcare Materials, 2020
- Progress and Promise of Nitric Oxide‐Releasing PlatformsAdvanced Science, 2018
- Nitric oxide releasing hydrogel promotes endothelial differentiation of mouse embryonic stem cellsActa Biomaterialia, 2017
- Activatable Near‐Infrared Probe for Fluorescence Imaging of γ‐Glutamyl Transpeptidase in Tumor Cells and In VivoChemistry – A European Journal, 2017
- A near-infrared “turn-on” fluorescent probe with a self-immolative linker for the in vivo quantitative detection and imaging of hydrogen sulfideBiosensors and Bioelectronics, 2017
- Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for GlaucomaAdvanced Materials, 2017
- PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cellsBioorganic & Medicinal Chemistry, 2015
- Nitroreductase-activated nitric oxide (NO) prodrugsBioorganic & Medicinal Chemistry Letters, 2013
- A Glycosylated Nitric Oxide Donor, β‐Gal‐NONOate, and its Site‐specific Antitumor ActivityArchiv der Pharmazie, 2006